MannKind Corp - ESG Rating & Company Profile powered by AI
The page displays a zero-cost E,S&G assessment for MannKind Corp. Full ESG analysis of MannKind Corp are accessed by signing in. Alternative corporations in the rating peer group for MannKind Corp are shown.
MannKind Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.1; made up of an environmental score of 0.0, social score of 1.6 and governance score of 1.6.
1.1
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1779 | Taisho Pharmaceutical Holdings Co Ltd | 1.2 | Low |
| 1779 | VBI Vaccines Inc | 1.2 | Low |
| 1810 | MannKind Corp | 1.1 | Low |
| 1810 | Captor Capital Corp | 1.1 | Low |
| 1810 | Century Therapeutics Inc | 1.1 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does MannKind Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes MannKind Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes MannKind Corp report the average age of the workforce?
Sign up for free to unlockDoes MannKind Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes MannKind Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes MannKind Corp disclose cybersecurity risks?
Sign up for free to unlockDoes MannKind Corp offer flexible work?
Sign up for free to unlockDoes MannKind Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes MannKind Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes MannKind Corp conduct supply chain audits?
Sign up for free to unlockDoes MannKind Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes MannKind Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes MannKind Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes MannKind Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes MannKind Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes MannKind Corp disclose water use targets?
Sign up for free to unlockDoes MannKind Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid MannKind Corp have a product recall in the last two years?
Sign up for free to unlockDoes MannKind Corp disclose incidents of discrimination?
Sign up for free to unlockDoes MannKind Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas MannKind Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes MannKind Corp disclose parental leave metrics?
Sign up for free to unlockDoes MannKind Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes MannKind Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes MannKind Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes MannKind Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes MannKind Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes MannKind Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs MannKind Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes MannKind Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes MannKind Corp disclose its waste policy?
Sign up for free to unlockDoes MannKind Corp report according to TCFD requirements?
Sign up for free to unlockDoes MannKind Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes MannKind Corp disclose energy use targets?
Sign up for free to unlockDoes MannKind Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes MannKind Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for MannKind Corp
These potential risks are based on the size, segment and geographies of the company.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.